Coherus stock falls as Junshi-partnered TIGIT Program ends
| CHRS Stock | USD 1.22 0.04 3.17% |
Slightly above 61% of Coherus BioSciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Coherus BioSciences suggests that many traders are alarmed. Coherus BioSciences' investing sentiment can be driven by a variety of factors including economic data, Coherus BioSciences' earnings reports, geopolitical events, and overall market trends.
Coherus |
Coherus BioSciences stock falls as the company terminates collaboration with Junshi Biosciences on a cancer drug called anti-TIGIT antibody. Read more here.
Read at seekingalpha.com
 |
Coherus BioSciences Fundamental Analysis
We analyze Coherus BioSciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Coherus BioSciences is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Coherus BioSciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Coherus BioSciences stock to make a market-neutral strategy. Peer analysis of Coherus BioSciences could also be used in its relative valuation, which is a method of valuing Coherus BioSciences by comparing valuation metrics with similar companies.
Peers
Coherus BioSciences Related Equities
| CTMX | CytomX Therapeutics | 3.92 | ||||
| BOLT | Bolt Biotherapeutics | 1.59 | ||||
| ASMB | Assembly Biosciences | 1.25 | ||||
| ACHL | Achilles Therapeutics | 0.93 | ||||
| SPRO | Spero Therapeutics | 0.88 | ||||
| NUVB | Nuvation Bio | 0.35 | ||||
| NXTC | NextCure | 2.50 | ||||
| TIL | Instil Bio | 9.39 |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.